ClinicalTrials.gg
CompletedNCT02148718RAPIDAUpdated Mar 1, 2018Results posted

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

A Phase 4 interventional study of adalimumab in Moderate to Severe Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-01.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
24th of 42
100 · median 143
Started
2014
with 3 others
Phase 4
13 of 42
4 open now
Registered
27th of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 24th largest by enrollment, is one of 4 that started in 2014, is one of 13 in phase 4, and was the 27th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.

03

Conditions studied

  • Moderate to Severe Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Crohn's disease (CD) diagnosed within, at least, the previous 4 months.
  • Patients with active luminal (Harvey-Bradshaw Index [HBI] ≥ 8) moderate to- severe CD.
  • No response to a full and adequate course of therapy with a and/or an .
  • If receiving any of the following treatments, their dose should be stable during the periods indicated:

    • Aminosalicylates for, at least, the last 4 weeks
    • Probiotics for, at least, the last 4 weeks
    • Analgesics for, at least, the last 4 weeks
    • Antidiarrheals for, at least, the last 4 weeks
    • CD-related antibiotics for, at least, the last 4 weeks
    • Azathioprine, 6-mercaptopurine or methotrexate for, at least, the last 12 weeks
  • If receiving any of the following treatments, their dose should not have been increase in the past two weeks (the dose reduction is permitted):

    • Oral budesonide (maximum dose of 9 mg/day)
    • Oral prednisone or equivalent (maximum dose of 40mg/day)

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any anti-Tumor Necrosis Factor agent
  • Surgical bowel resection within the previous 6 months, ostomy, extensive bowel resection (> 100 cm), short bowel syndrome
  • Fistulising Crohn's disease
  • Treatment with cyclosporine or tacrolimus within the previous 8 weeks
  • cardiac disease including unstable angina, acute myocardial infarction within six months from screening, congestive heart failure of worse than grade II New York criteria ( Functional Classification).
  • Subject with an ostomy or ileoanal pouch, proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis (Subjects with a previous ileo-rectal anastomosis are not excluded).
  • Screening laboratory values (according to central laboratory)
  • Known (HC) infection.
  • Serologic evidence of (HB) infection based on the results of testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and hepatitis B surface antibody (anti-HBs) antibodies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous injection

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Response at Day 4

    Clinical response defined as a decrease of at least 3 points in Harvey-Bradshaw Index (HBI) score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

    Time frame: Day 4

Secondary outcomes

  1. Percentage of Participants With Clinical Response at Week 1

    Clinical response defined as a decrease of at least 3 points in HBI score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

    Time frame: Week 1

  2. Percentage of Participants With Clinical Remission at Weeks 2 and 4

    Clinical remission defined as HBI \< 5. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

    Time frame: Weeks 2 and 4

  3. European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Index Score: Change From Baseline to Week 12

    The EQ-5D-3L is a standardized instrument for use as a measure of health-related quality of life (HRQoL) and consists of 2 components: 1. The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. 2. The EQ-5D visual analog scale (VAS) is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L Index Score are presented.

    Time frame: Baseline (Week 0) and Week 12

  4. European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Visual Analog Scale (VAS): Change From Baseline to Week 12

    The EQ-5D-3L is a standardized instrument for use as a measure of HRQoL and consists of 2 components: 1. The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. 2. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

    Time frame: Baseline (Week 0) and Week 12

  5. Inflammatory Bowel Disease Quality-36 (IBDQ-36) Questionnaire Overall Score: Change From Baseline to Week 12

    The IBDQ-36 is used to assess the HRQoL related to bowel symptoms. The IBDQ-36 overall score is calculated as the sum of thirty-six items, each scored on a 1 to 7 likert point scale, and ranges from 7 to 252. The highest score indicates the best HRQoL related to bowel symptoms. A positive change in IBDQ-36 overall score indicates an improvement in HRQoL due to inflammatory bowel disease. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

    Time frame: Baseline (Week 0) and Week 12

  6. Fatigue Impact Scale for Daily Use (D-FIS): Change From Baseline to Week 12

    The D-FIS is used to measure the impact of fatigue on the daily lives of persons. The D-FIS overall score was calculated as the sum of eight items, each scored on a 0 to 4 point scale, and ranges from 0 to 32. A higher score indicates a higher impact of fatigue on daily life. A negative change in D-FIS Overall Score means an improvement in HRQoL due to fatigue. Mean Baseline and mean change from Baseline to Week 12 are presented.

    Time frame: Baseline (Week 0) and Week 12

  7. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hemoglobin

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin, and coagulation (activated partial thromboplastin time \[aPTT\], international normalized ratio \[INR\], and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 are presented.

    Time frame: Baseline (Week 0) and Week 12

  8. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hematocrit

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  9. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  10. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Erythrocytes

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  11. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Sedimentation Rate (ESR)

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  12. Change From Baseline to Week 12 in Analytic Markers of Inflammation: C-reactive Protein (CRP)

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  13. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fecal Calprotectin

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  14. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Activated Partial Thromboplastin Time (aPTT)

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  15. Change From Baseline to Week 12 in Analytic Markers of Inflammation: International Normalized Ratio (INR)

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  16. Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fibrinogen

    Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

    Time frame: Baseline (Week 0) and Week 12

  17. Percentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 12

    The percentage of participants with clinical response (defined as decrease of at least 3 points in HBI score) at Day 4 or Week 1 and clinical remission (defined as a HBI \< 5) at Week 12.

    Time frame: Up to Week 12

07

Results

Posted Aug 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started86
Completed55
Not completed31
Withdrew: Protocol violation26
Withdrew: Discontinued study prematurely5

Outcome measures

PrimaryPercentage of Participants With Clinical Response at Day 4

Clinical response defined as a decrease of at least 3 points in Harvey-Bradshaw Index (HBI) score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

Time frame:
Day 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 4
percentage of participantsAdalimumab
Percentage of Participants With Clinical Response at Day 461.63 (50.51 to 71.92)
SecondaryPercentage of Participants With Clinical Response at Week 1

Clinical response defined as a decrease of at least 3 points in HBI score. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Week 1
percentage of participantsAdalimumab
Percentage of Participants With Clinical Response at Week 175.58 (65.13 to 84.20)
SecondaryPercentage of Participants With Clinical Remission at Weeks 2 and 4

Clinical remission defined as HBI \< 5. The HBI consists of only clinical parameters (general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and complications): The first 3 items are scored for the previous day. Patients with Crohn's disease who scored 3 or less on the HBI are very likely to be in remission. Patients with a score of 8 to 9 or higher are considered to have severe disease.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Weeks 2 and 4
percentage of participantsAdalimumab
Week 254.65 (43.55 to 65.42)
Week 462.79 (51.70 to 72.98)
SecondaryEuropean Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Index Score: Change From Baseline to Week 12

The EQ-5D-3L is a standardized instrument for use as a measure of health-related quality of life (HRQoL) and consists of 2 components: 1. The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. 2. The EQ-5D visual analog scale (VAS) is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L Index Score are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · units on a scale
European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Index Score: Change From Baseline to Week 12
units on a scaleAdalimumab
Baseline0.62 ± 0.22
Change from Baseline to Week 120.14 ± 0.25
SecondaryEuropean Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Visual Analog Scale (VAS): Change From Baseline to Week 12

The EQ-5D-3L is a standardized instrument for use as a measure of HRQoL and consists of 2 components: 1. The EQ-5D-3L Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 3 levels of severity for each dimension ('no problems', 'some problems', and 'extreme problems'). The level of severity reported on each of the EQ-5D-3L dimensions determines a unique health state. Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. 2. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in HRQoL. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · units on a scale
European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Visual Analog Scale (VAS): Change From Baseline to Week 12
units on a scaleAdalimumab
Baseline55.36 ± 18.52
Change from Baseline to Week 1215.37 ± 21.36
SecondaryInflammatory Bowel Disease Quality-36 (IBDQ-36) Questionnaire Overall Score: Change From Baseline to Week 12

The IBDQ-36 is used to assess the HRQoL related to bowel symptoms. The IBDQ-36 overall score is calculated as the sum of thirty-six items, each scored on a 1 to 7 likert point scale, and ranges from 7 to 252. The highest score indicates the best HRQoL related to bowel symptoms. A positive change in IBDQ-36 overall score indicates an improvement in HRQoL due to inflammatory bowel disease. Mean Baseline and mean change from Baseline to Week 12 in the EQ-5D-3L VAS are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · units on a scale
Inflammatory Bowel Disease Quality-36 (IBDQ-36) Questionnaire Overall Score: Change From Baseline to Week 12
units on a scaleAdalimumab
Baseline145.1 ± 35.83
Change from Baseline to Week 1244.72 ± 37.98
SecondaryFatigue Impact Scale for Daily Use (D-FIS): Change From Baseline to Week 12

The D-FIS is used to measure the impact of fatigue on the daily lives of persons. The D-FIS overall score was calculated as the sum of eight items, each scored on a 0 to 4 point scale, and ranges from 0 to 32. A higher score indicates a higher impact of fatigue on daily life. A negative change in D-FIS Overall Score means an improvement in HRQoL due to fatigue. Mean Baseline and mean change from Baseline to Week 12 are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · units on a scale
Fatigue Impact Scale for Daily Use (D-FIS): Change From Baseline to Week 12
units on a scaleAdalimumab
Baseline14.45 ± 8.53
Change from Baseline to Week 12-4.69 ± 8.44
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Hemoglobin

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin, and coagulation (activated partial thromboplastin time \[aPTT\], international normalized ratio \[INR\], and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · g/dL
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hemoglobin
g/dLAdalimumab
Baseline13.01 ± 1.40
Change from Baseline to Week 120.27 ± 0.97
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Hematocrit

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · % volume
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hematocrit
% volumeAdalimumab
Baseline39.47 ± 3.99
Change from Baseline to Week 120.86 ± 2.79
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · cellsx10^3/uL
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets
cellsx10^3/uLAdalimumab
Leukocytes Baseline8.11 ± 3.23
Leukocytes Change from Baseline to Week 12-1.62 ± 2.87
Neutrophils Baseline5.61 ± 2.86
Neutrophils Change from Baseline to Week 12-1.99 ± 2.87
Lymphocytes Baseline1.80 ± 0.94
Lymphocytes Change from Baseline to Week 120.39 ± 0.76
Monocytes Baseline0.50 ± 0.25
Monocytes Change from Baseline to Week 12-0.009 ± 0.219
Eosinophils Baseline0.17 ± 0.15
Eosinophils Change from Baseline to Week 12-0.010 ± 0.095
Basophils Baseline0.02 ± 0.02
Basophils Change from Baseline to Week 120.003 ± 0.033
Platelets Baseline316.1 ± 90.1
Platelets Change from Baseline to Week 12-40.4 ± 76.4
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Erythrocytes

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · cellsx10^6/uL
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Erythrocytes
cellsx10^6/uLAdalimumab
Baseline4.37 ± 0.51
Change from Baseline to Week 120.052 ± 0.308
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Sedimentation Rate (ESR)

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · mm/1h
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Sedimentation Rate (ESR)
mm/1hAdalimumab
Baseline19.49 ± 18.38
Change from Baseline to Week 12-7.48 ± 14.26
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: C-reactive Protein (CRP)

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · U/L
Change From Baseline to Week 12 in Analytic Markers of Inflammation: C-reactive Protein (CRP)
U/LAdalimumab
Baseline11.06 ± 16.2
Change from Baseline to Week 12-7.61 ± 16.4
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Fecal Calprotectin

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · mg/kg
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fecal Calprotectin
mg/kgAdalimumab
Baseline1,550.4 ± 2,798.4
Change from Baseline to Week 12-1,043.8 ± 2,895.3
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Activated Partial Thromboplastin Time (aPTT)

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · sec
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Activated Partial Thromboplastin Time (aPTT)
secAdalimumab
Baseline30.58 ± 3.89
Change from Baseline to Week 120.76 ± 3.97
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: International Normalized Ratio (INR)

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · ratio
Change From Baseline to Week 12 in Analytic Markers of Inflammation: International Normalized Ratio (INR)
ratioAdalimumab
Baseline1.05 ± 0.06
Change from Baseline to Week 120.02 ± 0.07
SecondaryChange From Baseline to Week 12 in Analytic Markers of Inflammation: Fibrinogen

Analytic markers of inflammation are hemogram (hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), erythrocytes, ESR, CRP, fecal calprotectin, and coagulation (aPTT, INR, and fibrinogen). Mean Baseline and mean change from Baseline to Week 12 for each parameter are presented.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · mg/dL
Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fibrinogen
mg/dLAdalimumab
Baseline374.5 ± 68.17
Change from Baseline to Week 12-43.6 ± 65.7
SecondaryPercentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 12

The percentage of participants with clinical response (defined as decrease of at least 3 points in HBI score) at Day 4 or Week 1 and clinical remission (defined as a HBI \< 5) at Week 12.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 12
percentage of participantsAdalimumab
Percentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 1258.90

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 70 days after the last dose of study drug (up to 20 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—2/86 (2.3%)35/86 (40.7%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
Crohn's diseaseGastrointestinal disorders1/86
PyrexiaGeneral disorders1/86
PneumoniaInfections and infestations1/86
Most frequent other events
Showing 10 of 50
Most frequent other events
EventAdalimumab
VomitingGastrointestinal disorders6/86
Abdominal massGastrointestinal disorders5/86
InfluenzaInfections and infestations4/86
ArthralgiaMusculoskeletal and connective tissue disorders4/86
PsoriasisSkin and subcutaneous tissue disorders4/86
Abdominal painGastrointestinal disorders3/86
DiarrhoeaGastrointestinal disorders3/86
Herpes virus infectionInfections and infestations3/86
PharyngitisInfections and infestations3/86
Urinary tract infectionInfections and infestations3/86

Baseline characteristics

Intent to Treat (ITT) population: all enrolled participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Adalimumab
Mean37.73 ± 12.16
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female49
Male37
Region of Enrollment
Region of Enrollment(participants)Adalimumab
Spain86
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Aug 2016, 26 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
May 28, 2014
StartActual
Jun 2014
Primary completionActual
Aug 2016
CompletionActual
Jan 2017
Results first posted
Aug 29, 2017
Last update
Mar 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02148718
Lead sponsor
AbbVie
Collaborators
Laboratorio Echevarne, Pivotal S.L.
Responsible party
Sponsor
First posted
May 28, 2014
Start date
Jun 2014
Primary completion
Aug 2016
Completion
Jan 2017
Results posted
Aug 29, 2017
Last update
Mar 1, 2018

Study contacts

Ignacio Marín, PhD
principal investigator · Hospital General Universitario Gregorio Marañon

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion